Drug intelligence / Profile preview

SBP-401

Development stage: Unknown
Lead developer: SPARK Biopharma
Modality: Small Molecules
Administration: Oral

Overview

SBP-401 is a small molecule drug developed by Sparkbiopharma. It acts as an inhibitor of High Mobility Group Protein B1 (HMGB1), a protein implicated in inflammation and fibrotic processes. The primary indication for SBP-401 is idiopathic pulmonary fibrosis, a progressive and fatal lung disease characterized by scarring of lung tissue. The drug has received Orphan Drug Designation from the U.S. FDA and has advanced to Phase 2 clinical trials for this indication[1][2][4]. Its mechanism involves inhibiting HMGB1, thereby potentially reducing inflammation and fibrosis in affected tissues.

Targets

HMGB1 (High mobility group protein B1)

Beyond the preview

Go deeper on SBP-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBP-401.

Explore the full profile